SIGY (Sigyn Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics ROE % Adjusted to Book Value?

Sigyn Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Sigyn Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Sigyn Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Sigyn Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Sigyn Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics ROE % Adjusted to Book Value Chart

Sigyn Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Sigyn Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sigyn Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Sigyn Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sigyn Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's ROE % Adjusted to Book Value falls into.

Sigyn Therapeutics ROE % Adjusted to Book Value Calculation

Sigyn Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Sigyn Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Sigyn Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212